Abstract: |
We studied the effect of tumor size on monoclonal antibody (mAb) in a murine hepatic model. Intrasplenic injection of HT‐29 LMM metastatic human colon cancer cell line reproducibly results in hepatic metastases formation in congenitally athymic mice. HT‐29‐15, a murine mAb of the IgGI class reactive with the HT‐29 LMM cell line, and BL‐3, an isotype‐matched control mAb, were labeled with iodine 125. Labeled mAbs were injected intravenously into mice with hepatic metastases. Animals were sacrificed on day 5, and tumor and normal tissue weighed and counted. Specific mAb uptake (percent injected dose per gram, %ID/g) by hepatic metastases (5.16 ± 3.96) was significantly greater than nonspecific uptake (1.41 ± 0.42) (P < 0.001). %ID/g of tumor was dependent upon the mAb used, and was independent of tumor weight; consequently, a linear correlation between tumor weight and total uptake (%ID) for specific mAb (r = 0.88, P < 0.0001) and nonspecific mAb (r = 0.99, P < 0.0001) administration was demonstrated. We have shown both specific and nonspecific mAb uptake per gram of tumor to be a constant for the given mAb/tumor system and with uptake of mAb to be linearly related to tumor weight. © 1992 Wiley‐Liss, Inc. Copyright © 1992 Wiley‐Liss, Inc., A Wiley Company |
Keywords: |
nonhuman; conference paper; adenocarcinoma; mouse; animal; mice; animal tissue; tumor volume; cell line; animal experiment; colonic neoplasms; tumor cell culture; monoclonal antibody; liver metastasis; antibodies, monoclonal; iodine 125; isotope labeling; nude mouse; tissue distribution; iodine radioisotopes; mice, nude; colorectal tumor; neoplasm transplantation; disease models, animal; hepatic metastases; splenic neoplasms; athymic mice; liver neoplasms, experimental; colorectal neoplasm; human; priority journal; support, non-u.s. gov't
|